Platelet reactions and immune processes. II. The inhibition of platelet aggregation by complement inhibitors.
D000447:Aldehydes / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000276:immunology; D002396:Catechols / Q000494:pharmacology; D002462:Cell Membrane / Q000276:immunology; D002738:Chloroquine / Q000494:pharmacology; D003078:Colchicine / Q000494:pharmacology; D003094:Collagen; D003168:Complement Fixation Tests; D003169:Complement Inactivator Proteins; D006139:Guaiacol / Q000494:pharmacology; D006801:Humans; D007841:Latex Fixation Tests; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D010653:Phenylbutazone / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects; D012118:Resorcinols / Q000494:pharmacology; D012459:Salicylates / Q000494:pharmacology; D012828:Silicones; D012964:Sodium / Q000494:pharmacology; D013442:Sulfinpyrazone / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D000447:Aldehydes; D002396:Catechols; D003169:Complement Inactivator Proteins; D012118:Resorcinols; D012459:Salicylates; D012828:Silicones; D062367:ortho-Aminobenzoates; D006139:Guaiacol; D002738:Chloroquine; D003094:Collagen; D012964:Sodium; D010653:Phenylbutazone; D003078:Colchicine; D013442:Sulfinpyrazone